0001610717-23-000186.txt : 20230620
0001610717-23-000186.hdr.sgml : 20230620
20230620165914
ACCESSION NUMBER: 0001610717-23-000186
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230615
FILED AS OF DATE: 20230620
DATE AS OF CHANGE: 20230620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morrison Scott W
CENTRAL INDEX KEY: 0001662426
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37719
FILM NUMBER: 231026057
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 400 EAST JAMIE COURT SUITE 101
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Corvus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001626971
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464670809
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 863 MITTEN ROAD
STREET 2: SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: (650) 900-4520
MAIL ADDRESS:
STREET 1: 863 MITTEN ROAD
STREET 2: SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
4
1
form4.xml
X0407
4
2023-06-15
0001626971
Corvus Pharmaceuticals, Inc.
CRVS
0001662426
Morrison Scott W
C/O CORVUS PHARMACEUTICALS, INC.
863 MITTEN ROAD, SUITE 102
BURLINGAME
CA
94010
true
false
Stock Option (Right to Buy)
2.49
2023-06-15
4
A
0
15000
0
A
2033-06-15
Common Stock
15000
15000
D
The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
/s/ Leiv Lea, as Attorney-in-Fact for Scott W. Morrison
2023-06-20